Psoriasis News and Research

Latest Psoriasis News and Research

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Janssen Inc. has filed a New Drug Submission (NDS) to Health Canada for the investigational drug abiraterone acetate administered with prednisone for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. Submissions for abiraterone acetate have also been filed with health authorities in the United States and Europe.

23 Dec 2010

Isotechnika, Paladin receive screening acceptance for Voclera for approval in Canada

Isotechnika Pharma Inc. and Paladin Labs Inc. announced today that they have submitted the dossier and received screening acceptance for VocleraTM (voclosporin) for approval in the Canadian market. VocleraTM is a novel immunosuppressive drug in the class of calcineurin inhibitors and is indicated for the treatment of moderate to severe psoriasis.

20 Dec 2010

Study finds second skin barrier structure may play a role in eczema development

Like a fence or barricade intended to stop unwanted intruders, the skin serves as a barrier protecting the body from the hundreds of allergens, irritants, pollutants and microbes people come in contact with every day.

20 Dec 2010

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Anacor Pharmaceuticals announced today that enrollment has been initiated and the first patient has been dosed in the Phase 3 program of AN2690, a topical antifungal product candidate for the treatment of onychomycosis.

16 Dec 2010

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.

16 Dec 2010

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

15 Dec 2010

Provectus commences PH-10 Phase 2c trial for psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.

14 Dec 2010

BUSM professor wins 2010 Van Slyke Award for seminal contributions to laboratory medicine

Michael F. Holick, PhD, MD, a professor at Boston University School of Medicine (BUSM), is the recipient of the 2010 Van Slyke Award from the American Academy for Clinical Chemistry New York Metro Section.

14 Dec 2010

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Tanabe Research Laboratories U.S.A. Inc., (TRL) announced today that it has entered into a partnership with Anaphore Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's proprietary Atrimer™ technology.

13 Dec 2010

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, and Galderma, a global leading pharmaceutical company dedicated exclusively to the field of dermatology, announce the expansion of their multi-year collaboration agreement. Based on positive data assessing the activity of NovaBay's Aganocide compounds against impetigo, Galderma has agreed to exercise its option for this indication.

6 Dec 2010

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of a new concept in the Current Opinion in Lipidology evaluating oxidized phospholipid analogs as potential treatments for chronic inflammatory diseases.

2 Dec 2010

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

RegeneRx Biopharmaceuticals, Inc. announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.

2 Dec 2010

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor Pharmaceuticals, the University of California San Francisco (UCSF) Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center (NYBC) today announced the establishment of a research and development collaboration to discover new drug therapies for the treatment of river blindness (onchocerciasis), a parasitic disease that is the second leading cause of infectious blindness worldwide, and is most prevalent in Africa.

1 Dec 2010

Anacor completes initial public offering of common stock

Anacor Pharmaceuticals, Inc. today announced the completion of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.

30 Nov 2010

Anacor prices initial public offering of common stock

Anacor Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 12,000,000 shares of its common stock at a price of $5.00 per share.

24 Nov 2010

Provectus reports progress in PV-10 program for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports continued progress in its compassionate use program for PV-10. The program currently has enrolled more than 40 patients, ten of whom are expanded access patients from the company's Phase 2 trial of PV-10 for metastatic melanoma, as well as more than 30 new patients.

24 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.

16 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

Psoriasis News and Research

Latest Psoriasis News and Research

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Janssen files abiraterone acetate NDS with Health Canada for metastatic, advanced prostate cancer

Isotechnika, Paladin receive screening acceptance for Voclera for approval in Canada

Study finds second skin barrier structure may play a role in eczema development

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Provectus commences PH-10 Phase 2c trial for psoriasis

BUSM professor wins 2010 Van Slyke Award for seminal contributions to laboratory medicine

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

Current Opinion in Lipidology journal publishes data on VB-201 for immune-mediated disorders

RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents

Anacor, UCSF and NYBC collaborate to discover drug therapies for river blindness

Anacor completes initial public offering of common stock

Anacor prices initial public offering of common stock

Provectus reports progress in PV-10 program for metastatic melanoma

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forensics and toxicology - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Psoriasis News and Research

Latest Psoriasis News and Research

Forensics and toxicology - Industry Focus eBook eBook

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in